SEPTInvestingStart Free

RNA 10-Q: SEC filing

Atrium Therapeutics, Inc.

Filed with the SEC on · accession 0001193125-26-458471

RNA filed a 10-Q (quarterly report) with the SEC on Nov 12, 2026. Atrium Therapeutics, Inc. (RNA) filed its Q3 2026 Form 10-Q, reporting financial results for the quarter ended September 30, 2026. The stock moved -5.8% by the first close after the filing.

Summary of the filing

Atrium Therapeutics, Inc. (RNA) filed its Q3 2026 Form 10-Q, reporting financial results for the quarter ended September 30, 2026. The filing reflects the company's operations as a standalone entity following its spin-off from its former parent, including collaboration agreements with BMS and Eli Lilly.

For details, click here →How to read a 10-Q →

Key details

Collaboration partnerBristol Myers Squibb
Collaboration partnerEli Lilly and Company
Mentioned in filingAvidity Biosciences, Inc.

How RNA stock reacted

Close before

$7.96

Nov 11, 2026

First close after

-5.78%

$7.50

5 trading days

—

Since filing

—

✦ Ask GOAX AI about this filing — what it means for RNA, what changed since its last filings and what to watch next.

Try it free for 7 days

🔔 Want to stay updated on new SEC filings for RNA?

Click here

Frequently asked questions

What did RNA file with the SEC on Nov 12, 2026?

RNA filed a 10-Q (SEC filing). Atrium Therapeutics, Inc. (RNA) filed its Q3 2026 Form 10-Q, reporting financial results for the quarter ended September 30, 2026. The filing reflects the company's operations as a standalone entity following its spin-off from its former parent, including collaboration agreements with BMS and Eli Lilly.

How do I read a 10-Q?

The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.

Why are SEC filings important?

Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.

How did RNA stock react to this filing?

RNA closed at $7.96 before the filing and $7.50 on Nov 12, 2026 (-5.78%).

Other RNA SEC filings

Get alerts when RNA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.

Try SEPT free for 7 days
RNA overviewRNA analysisRNA newsLatest SEC filings